A summary article of a study recently published by Consiglio et al. in Cell.

This study focus on the rare cases when children develop Multisystem Inflammatory Syndrome in Children (MIS-C) in response to infection by the SARS-CoV-2 virus. Typically in these cases the syndrome manifests four to six weeks after infection, producing high fever, organ dysfunction, and strongly elevated markers of inflammation.

Interestingly the systems-level analysis described in the study reveal that these children have an immunological profile that is quite distinct from both the symptomatically overlapping Kawasaki disease, and severe COVID-19 in adults. These findings could be used to develop better immunomodulatory therapies for MIS-C. 

These findings could be used to develop better immunomodulatory therapies for mitigating hyperinflammation and long-term tissue damage